The relationship among risk factor clustering, abdominal obesity, and residual risk for cardiovascular events

Area of Science:

• Cardiovascular Medicine and Endocrinology
• Metabolic Syndrome Research

Background:

• Established therapies like statins and ACE inhibitors reduce cardiovascular events but leave significant residual risk.
• Genetic and epigenetic factors contribute to residual risk but are difficult to modify.
• Abdominal obesity is a key component of metabolic syndrome, increasing cardiovascular disease and type 2 diabetes risk.

Purpose of the Study:

• To identify and target modifiable factors contributing to residual cardiometabolic risk.
• To evaluate abdominal obesity as a therapeutic target for reducing residual cardiovascular risk.
• To highlight the utility of waist circumference measurement in assessing cardiometabolic risk.

Main Methods:

• Review of existing literature on cardiovascular risk reduction strategies.
• Analysis of the role of abdominal obesity in cardiometabolic risk.
• Assessment of waist circumference as a correlate and predictor of abdominal obesity and risk.

Main Results:

• Abdominal obesity is a significant, modifiable contributor to residual cardiometabolic risk.
• Waist circumference measurement is a practical and effective tool for identifying individuals at risk.
• Dietary, behavioral, and pharmacological interventions can help mitigate risk associated with abdominal obesity.

Conclusions:

• Targeting abdominal obesity is a crucial strategy for lowering residual cardiovascular risk.
• Waist circumference measurement provides valuable insight into cardiometabolic risk assessment.
• Comprehensive interventions are necessary to address the multifaceted nature of residual cardiovascular risk.